Ignet

Gene Information

Gene symbol: CD22

Gene name: CD22 molecule

HGNC ID: 1643

Synonyms: SIGLEC-2, SIGLEC2

Related Genes

#	Gene Symbol	Number of hits
1	B3GAT1	1 hits
2	BCL2	1 hits
3	BTLA	1 hits
4	C5AR1	1 hits
5	CCR6	1 hits
6	CD163	1 hits
7	CD19	1 hits
8	CD209	1 hits
9	CD27	1 hits
10	CD38	1 hits
11	CD4	1 hits
12	CD40	1 hits
13	CD68	1 hits
14	CD81	1 hits
15	CD86	1 hits
16	CD8A	1 hits
17	COL1A1	1 hits
18	CR2	1 hits
19	FCER2	1 hits
20	FCGR2A	1 hits
21	FUT4	1 hits
22	IL2RA	1 hits
23	INPP5D	1 hits
24	ITGA4	1 hits
25	ITGB1	1 hits
26	MME	1 hits
27	MS4A1	1 hits
28	PDCD1	1 hits
29	PTPN6	1 hits
30	PTPRC	1 hits
31	SELL	1 hits

Related Sentences

#	PMID	Sentence
1	1593713	Increases in CD3+ T cell infiltration of the lamina propria and that of the CD4+ "Helper" subset which predominated were significant up to 3 months post-therapy and these cells showed evidence of increased immunological activation as shown by increased interleukin-2 receptor and MHC Class II antigen expression.
2	1593713	There were also significant increases in CD68+ macrophage and the incidence of CD22+ B cell aggregates but CD57+ NK cells were sparse both before and after therapy.
3	1593713	Also the degree of T cell infiltration (CD3, CD4 and CD8) was significantly greater in the eight patients deemed to have had a complete response compared to those seven with a partial response or treatment failure.
4	2683316	Leucocyte subsets were enumerated with a panel of monoclonal antibodies which included CD3, CD4, CD8, TQ1, Leu7, CD15, HLA-DR, CD25, CD22.
5	2683316	We demonstrated in the bladders of patients treated with BCG a particular lymphocyte population; the major subset was an inducer (CD4+, TQ1-) which was activated (CD25+, HLA-DR+) and associated with polymorphonuclear eosinophils.
6	9597145	Recent findings in B lymphocytes have clearly illustrated that these external inputs affect the magnitude and duration of the intracellular calcium response, which in turn contributes to differential triggering of the transcriptional regulators NF kappa B, JNK, NFAT, and ERK.
7	9597145	The regulation of calcium responses involves a network of tyrosine kinases (e.g. lyn, syk), tyrosine or lipid phosphatases (CD45, SHP-1, SHIP), and accessory molecules (CD21/CD19, CD22, FcR gamma 2b).
8	11252930	Clinical trials with antibodies have mostly targeted CD20, which is present on 95% of all B-cell lymphomas, as well as CD19 and CD22.
9	11722986	Iodine-131, Yttrium-90, and Copper-67 labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and other cell surface antigens have been tested and demonstrate higher overall response rates (50-80%) and complete response rates (20-40%) than unlabeled antibodies.
10	15947095	B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model.
11	15947095	The effect of B-cell depletion was further studied in a murine collagen-induced arthritis (CIA) model and a respiratory syncytial virus (RSV) vaccination model.
12	15947095	These results demonstrate for the first time that only B-cell reduction but not type II collagen antibody levels correlate with the prevention of arthritis and represent key insights into the role of CD22-targeted B-cell depletion in mouse autoimmunity and vaccination models.
13	17658616	This screening identified mAbs that consistently reacted with both putative myeloid (CD10, CD22, CD23, CD27, CD29, CD32, CD49d, CD81, CD86, CD88, CD163, CD165) and B cell (CD10, CD22, CD23, CD27, CD29, CD32, CD49d, CD81, CD86, CD88, CD165) activation or differentiation antigens.
14	20227905	Furthermore, glyconanoparticles and glycodendrimers have been used for specific targeting of lectins of the immune system such as selectins, DC-SIGN, and CD22.
15	25320372	In this article, we highlight these promising approaches, such as the combination of anti-CD20 antibodies with immunomodulatory drugs, with mAbs directed against other surface antigens such as CD22, with immunomodulatory antibodies such as PD-1, or with inhibitors of key steps in the B-cell receptor pathway signaling.
16	26151223	Here we characterized rhesus macaque MZ B cells, present in secondary lymphoid tissue but not peripheral blood, as CD19(+), CD20(+), CD21(hi), IgM(+), CD22(+), CD38(+), BTLA(+), CD40(+), CCR6(+) and BCL-2(+).